Abstract: The present invention relates to the use of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and/or SERPINA3 as biomarkers of the Mineralocorticoid Receptor (MR) activation in a patient. More particularly, the present invention relates to a method for predicting the responsiveness of a patient to a treatment with a MR antagonist or an aldosterone synthase inhibitor, said method comprising determining in a biological sample obtained from said patient the expression level of the NGAL gene and/or of the SERPINA3 gene.
Type:
Application
Filed:
October 21, 2009
Publication date:
October 20, 2011
Applicant:
INSERM (Institut National de la Sante et de la Rec herche Medicale)
Abstract: A method is disclosed for administering a DHEA derivative or a physiologically acceptable salt, ester or ether thereof for one of decreasing body weight, reducing adipose tissue, increasing endurance, as an anti-aging compound and generating production of red blood cells.
Abstract: Methods of treating a subject with a traumatic central nervous system injury, more particularly, a traumatic brain injury, are provided. The methods comprise a therapy comprising a constant or a two-level dosing regime of progesterone. In one method, a subject in need thereof is administered at least one cycle of therapy, wherein the cycle of therapy comprises administering a therapeutically effective two-level intravenous dosing regime of progesterone. The two-level dosing regime comprises a first time period, wherein a higher hourly dose of progesterone is administered to the subject, followed by a second time period, wherein a lower hourly dose of progesterone is administered to the subject.
Type:
Application
Filed:
March 10, 2011
Publication date:
September 15, 2011
Inventors:
Stuart W. Hoffman, Arthur L. Kellermann, Donald G. Stein, David W. Wright, Douglas W. Lowery-North
Abstract: The present invention relates to a method for preparing microspheres and microspheres prepared thereby, more particularly to a method for preparing a polymeric microsphere, including preparing an emulsion including a polymer compound, a drug, a water-insoluble organic solvent and a dispersion solvent and adding to the prepared emulsion a base or an acid to remove the water-insoluble organic solvent from the emulsion, a polymeric microsphere prepared thereby, and a composition for drug delivery including the microsphere. According to the present invention, a drug-containing polymer microsphere may be prepared quickly and simply without the solvent evaporation or solvent extraction process, thereby reducing water consumption and minimizing wastewater generation.
Type:
Application
Filed:
May 12, 2011
Publication date:
September 8, 2011
Applicants:
EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION, SK CHEMICALS CO., LTD.
Abstract: The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3?-yl)-?-D-glucopyranosiduronate, 16?,3?-dihydroxy-5?-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.
Abstract: The use of an aromatase inhibitor (AI) in the preparation of a medicament for use in inducing ovulation in a female suffering from anovulatory infertility which comprises administering to said female a single dose of the at least one aromatase inhibitor. The use of an aromatase inhibitor (AI) for the preparation of a medicament comprising a single dose of at least one aromatase inhibitor (AI) for administration to an ovulating female suffering from unexplained infertility or other types of ovulatory infertility early in one or more menstrual cycles. Such a medicament may also be administered to an anovulatory female in combination with a plurality of daily doses of follicle stimulating hormone (FSH) whereby the dosage levels of FSH may be reduced. The use of AI in the preparation of a medicament for administration to a female who is a poor responder to FSH, which comprises a combination of a single dose of AI with a plurality of daily doses of FSH is also disclosed.
Type:
Grant
Filed:
April 17, 2002
Date of Patent:
August 30, 2011
Assignee:
Ares Trading S.A.
Inventors:
Robert F. Casper, Mohamed F. M. Mitwally
Abstract: Compositions comprising a nanoparticulate corticosteroid and an antihistamine are described. The compositions are useful in the prophylaxis and chronic treatment of asthma in adults and pediatric patients and for the relief of allergic conjunctivitis, symptoms of seasonal allergic rhinitis in adults and pediatric patients. Combining an antihistamine with a nanoparticulate corticosteroid in a single formulation results in improved efficacy.
Type:
Grant
Filed:
March 23, 2006
Date of Patent:
August 23, 2011
Assignee:
Elan Pharma International Limited
Inventors:
Gary Liversidge, Scott Jenkins, H. William Bosch, Christian F. Wertz
Abstract: The subject invention pertains to the treatment of tumors and cancerous tissues and the prevention of tumorigenesis and malignant transformation through the modulation of JAK/STAT3 intracellular signaling. The subject invention concerns pharmaceutical compositions containing cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof, to a patient, wherein the tumor is characterized by the constitutive activation of the JAK/STAT3 intracellular signaling pathway. The present invention further pertains to methods of moderating the JAK and/or STAT3 signaling pathways in vitro or in vivo using cucurbitacin I, or a pharmaceutically acceptable salt or analog therof. Another aspect of the present invention concerns a method for screening candidate compounds for JAK AND/or STAT3 inhibition and anti-tumor activity.
Abstract: The present invention provides compositions and methods for noninvasive delivery of therapeutic agents across an intact tympanic membrane. For example, the compositions include a penetration enhancer which increases the flux of a therapeutic agent (e.g., antibiotic) across the tympanic membrane. Such compositions are particularly useful in the treatment of otitis media. Additionally, the composition may include a sustained release agents that, in some embodiments form sustained release reservoirs, in situ, once administered to a patient.
Type:
Application
Filed:
May 19, 2009
Publication date:
July 7, 2011
Applicants:
Massachusettes Institute of Technology, Children's Medical Center Corporation
Inventors:
Emmanuel John Simons, Todd R. Hoare, Daniel S. Kohane, Robert S. Langer
Abstract: The invention generally pertains to the discovery that agents capable of inhibiting the binding of cortisol to its receptor can be used in methods for treating patients diagnosed with Amyotrophic Lateral Sclerosis (ALS).
Abstract: Nasal pharmaceutical formulations comprising a drug substance having a specific particle size distribution profile are disclosed herein. Such profile provides increased bioavailability, increased efficacy or prolonged therapeutic effect of the drug substance when administered intranasally. The formulations of the present invention may comprise one or more corticosteroids having a specific particle size distribution profile. In a preferred embodiment, the corticosteroid is fluticasone or a pharmaceutically acceptable derivative thereof for the treatment of one or more symptoms of rhinitis. Preferably, the drug substance is fluticasone propionate. The formulations herein may be provided as an aqueous suspension suitable for inhalation via the intranasal route.
Abstract: The present invention provides systems for developing and/or testing therapies for prenatal diseases and conditions including Down Syndrome. The present invention also provides diagnostic methods for Down Syndrome involving, in some embodiments, gene expression analyses of fetal RNA and/or detection of expression of particular genes involved in Down Syndrome. Also provided are microarrays and kits useful in prenatal diagnostic applications.
Type:
Application
Filed:
June 1, 2009
Publication date:
June 23, 2011
Inventors:
Donna Slonim, Kirby Johnson, Diana Bianchi
Abstract: The present invention in one aspect relates generally to the identification, provision and use of a plurality of biomarkers to provide risk assessment of a woman for preterm delivery, and products and processes related thereto. In one aspect, a novel plurality of biomarkers as described herein is provided to determine a risk for preterm delivery. In one aspect are methods for determining a risk of preterm delivery in a subject. In another aspect are methods of predicting the likelihood of preterm delivery in a subject. In yet another aspect are methods for identifying subjects at risk of preterm delivery, and kits for use in the method In yet another aspect are nucleic acid arrays comprising nucleic acid probes that hybridize to preterm delivery marker genes.
Type:
Application
Filed:
May 1, 2009
Publication date:
June 16, 2011
Inventors:
Michelle A Williams, Daniel A. Enquobahrie
Abstract: Steroid compounds processing a hydrogen donor in 3beta position, either in the form of a hydroxy- or a sulfate group, function as efficient blockers of the 3alpha-hydroxy-pregnan-steroid action and thus have utility as therapeutic substances for the prevention and/or treatment of steroid related CNS disorders. Treatment methods based on the administration of these substances are disclosed, and these substances either alone or in combination are also suggested for the manufacture of pharmaceuticals for the treatment of many specific steroid induced CNS disorders.
Type:
Grant
Filed:
December 20, 2002
Date of Patent:
June 14, 2011
Assignee:
Umecrine AB
Inventors:
Torbjorn Backstrom, Per Lundgren, Ming-De Wang, Inga-Maj Johansson
Abstract: Described herein are bismethylene-17? carbolactone derivatives having progestational and/or antimineralocorticoid and/or aldosterone antagonistic activity. Also described herein are methods of preparing and using these novel compounds.
Type:
Grant
Filed:
March 4, 2009
Date of Patent:
June 14, 2011
Assignee:
Everstra, Inc.
Inventors:
Klaus Nickisch, Pemmaranu N. Rao, James W. Cessac, Anne Marie Simmons
Abstract: The present invention relates to a pharmaceutical composition comprising micronized progesterone, soya bean lecithin, and at least one oil selected from the group consisting of sunflower oil, olive oil, sesame see oil, colza oil, almond oil, to the method for the preparation thereof and to the uses thereof for treating a physiological condition linked to insufficiency of progesterone secretion.
Abstract: A process for preparing an intermediate compound of formula (II) where X is as defined in the specification, R1 is haloalkyl, alkyl, alkenyl, cycloalkyl, carboxyalkyl, alkoxycarbonylalkyl, aryl or arylalkyl; R2, R3, R4 and R5 are organic groups as defined in the specification, which process comprises aromatisation of a compound of formula (III) where R1, R2, R3, n, X and R5 are as defined in relation to formula (II) and R4? is a group R4 or a precursor group thereof, and thereafter if necessary or desired, carrying out one or more of the following steps: (i) removing any hydroxy-protecting groups R; (ii) converting a precursor group R4? to a group R4, or where R4? is a group R4, converting it to a different such group. Compounds obtained are useful intermediates for example in the preparation of fulvestrant. Novel intermediates are also claimed.
Type:
Grant
Filed:
October 9, 2001
Date of Patent:
May 24, 2011
Assignee:
AstraZeneca AB
Inventors:
Robert Stevenson, Fraser Witton Kerr, Anthony Raymond Lane, Eve Joanne Brazier, Phillip John Hogan, David Dermot Patrick Laffan
Abstract: Provided herein is a stable pharmaceutical product comprising a dry powder inhalation device, and a pharmaceutical composition that comprises R,R-Formoterol L-tartrate salt, in particular crystalline R,R-formoterol L-tartrate; and ciclesonide.
Abstract: The present invention relates to the treatment of protozoal diseases by administering cytotoxic and/or cytostatic compounds, in particular those used in anticancer therapy, to patients. In particular, the invention relates to the use of anticancer agents that can penetrate into the CNS for treatment of late stage African sleeping sickness or cerebral malaria.
Abstract: Novel methods for the medical treatment and/or inhibition of the development of osteoporosis, breast cancer, hypercholesterolemia, hyperlipidemia or atherosclerosis in susceptible warm-blooded animals including humans involving administration of selective estrogen receptor modulator particularly compounds having the general structure: and an amount of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-ene-3?,17?-diol and compounds converted in vivo to one of the foregoing precursor. Further administration of bisphosphonates in combination with selective estrogen receptor modulators and/or sex steroid precursor is disclosed for the medical treatment and/or inhibition of the development of osteoporosis. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.
Abstract: A method of preparing and composition of bioavailable hydrophobic, poorly water soluble drugs. It uses for example, lecithin, sterol, a calcium salt, and solvent; mixing to form liposomes and then the solvent driven off; the ratios used and physical form differ from others, and maximize performance.
Abstract: A composition having at least one modified or derivative of 1,4,6-androstatriene-3,17-dione (“ATD”) will improve the health of mammalian subjects. The improvement of health is achieved with the administration of an effective amount of at least one modified or derivative of 1,4,6-androstatriene-3,17-dione. Particularly, health is improved for a subject suffering with a gynecomastia and/or estrogen-dependent cancer. Also, subjects recovering from steroid misuse/abuse will benefit from treatment in accordance with the present invention.
Abstract: The invention relates to the development of a method and pharmaceutical compositions for obtaining plasmatic progesterone levels in humans and for maintaining a plasmatic progesterone concentration between 42 and 3.5 ng/mL for eight days as well as maximum plasmatic concentrations (Cmax) between 12 and 42 ng/mL, sufficient for use in different therapeutic options that require said progesterone concentrations.
Type:
Application
Filed:
April 14, 2008
Publication date:
May 5, 2011
Applicant:
POSI VISIONARY SOLUTIONS LLP
Inventors:
John Claude Savoir Vilboeuf, Aurelio De Gyves Lopez Lena, Juan Ramon Martinez de Leon
Abstract: The present invention relates to implantable or insertable medical devices that treat uterine and urological conditions that cause chronic pelvic pain and other symptoms. In another aspect, the present invention relates to methods of manufacturing such implantable or insertable medical devices.
Abstract: The present invention provides compositions and methods for providing sustained release of an active agent through the skin of a subject, wherein a pharmaceutical percutaneous composition comprises at least one fatty acid ester and a therapeutically effective amount of active agent.
Abstract: Steroid compounds possessing a hydrogen donor in 3beta position, either in the form of a hydroxy- or a sulfate group, function as efficient blockers of the 3alpha-hydroxy-pregnan-steroid action and thus have utility as therapeutic substances for the prevention and/or treatment of steroid related CNS disorders. Treatment methods based on the administration of these substances are disclosed, and these substances either alone or in combination are also suggested for the manufacture of pharmaceuticals for the treatment of many specific steroid induced CNS disorders.
Type:
Application
Filed:
January 7, 2011
Publication date:
April 28, 2011
Applicant:
UMECRINE COGNITION AB
Inventors:
Torbjorn Backstrom, Per Lundgren, Ming-De Wang, Inga-Maj Johansson
Abstract: A pharmaceutical controlled release composition in solid dosage form is provided which comprises (I) a water-swellable linear polymer obtainable by reacting together: (a) a dried polyethylene oxide; (b) a dried C5 to C20 diol; and (c) a Bifunctional diisocyanate; and (II) a releasable pharmaceutically active agent.
Abstract: The invention relates to 21-keto triterpene compounds of formula (I): wherein R1, X, and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the invention also relates to methods for prevention or treatment of HIV infections by administering therapeutically effective amounts of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof to a subject in need of such treatment.
Type:
Application
Filed:
July 3, 2010
Publication date:
March 31, 2011
Inventors:
Christophe Moinet, Liliane Halab, Nathalie Turcotte, Monica Bubenik, Marc Courchesne, Carl Poisson, Oswy Z. Pereira, Paul Nguyen-Ba, Bingcan Liu, Nathalie Chauret, Caroline Cadilhac, Laval Chan Chun Kong
Abstract: This invention provides a system for compounding a pharmaceutical product for hormone replacement therapy. The system has a set of concentrated reagent compositions, each containing one or more steroid hormones dissolved in one or more solvents. The needs of each consumer are ascertained, and a pharmaceutical product is compounded for them using the concentrated reagent compositions. Each product has a custom tailored combination of steroid hormones at a concentration that is therapeutically effective for the consumer in accordance with their needs.
Abstract: The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3?-hydroxy-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 1?,3?-dihydroxy-4?-fluoroandrost-5-ene-17-one, 1?,3?,17?-trihydroxy-4?-fluoroandrost-5-ene, 1?,3?-dihydroxy-6?-bromoandrost-5-ene, 1?-fluoro-3?,12?-dihydroxyandrost-5-ene-17-one, 1?-fluoro-3?,4?-dihydroxyandrost-5-ene and 4?-fluoro-3?,6?,17?-trihydroxyandrostane.
Abstract: The present invention relates to novel Heterocyclic Ether or Thioether Derivatives, compositions comprising the Heterocyclic Ether or Thioether Derivatives, and methods for using the Heterocyclic Ether or Thioether Derivatives for treating or preventing a proliferative disorder, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral infection, a fungal infection, or a disorder related to the activity of a protein kinase.
Type:
Application
Filed:
October 27, 2008
Publication date:
February 24, 2011
Inventors:
Gerald W. Shipps, JR., Matthew Richards, Cliff C. Cheng, Xiaohua Huang
Abstract: Steroid compounds processing a hydrogen donor in 3beta position, either in the form of a hydroxy- or a sulfate group, function as efficient blockers of the 3alpha-hydroxy-pregnan-steroid action and thus have utility as therapeutic substances for the prevention and/or treatment of steroid related CNS disorders. Treatment methods based on the administration of these substances are disclosed, and these substances either alone or in combination are also suggested for the manufacture of pharmaceuticals for the treatment of many specific steroid induced CNS disorders.
Type:
Grant
Filed:
December 20, 2002
Date of Patent:
February 15, 2011
Assignee:
Umecrine AB
Inventors:
Torbjorn Backstrom, Per Lundgren, Ming-De Wang, Inga-Maj Johansson
Abstract: Disclosed are compounds such as 5?-androstane-3,6,17-trione, formulations comprising said compounds, and methods of use thereof to stimulate endogenous testosterone production and improve athletic performance and libido.
Abstract: The invention provides a device and a compound for the prevention and/or treatment of uterine fibroids in human patients, wherein the compound is dispensed from the device and is administered locally to the uterine tissue.
Abstract: A method for treating or preventing spontaneous preterm birth in pregnant women and improving neonatal morbidity and mortality. The method includes administering to a pregnant woman in need thereof an effective amount of progesterone sufficient to prolong gestation by minimizing the shortening or effacing of her cervix. Treatment and prophylaxis with progesterone in pregnant women having symptoms of short cervix has been clinically shown to increase neonatal health.
Type:
Grant
Filed:
July 6, 2009
Date of Patent:
February 8, 2011
Inventors:
George Creasy, John M. O'Brien, Jr., Emily A. DeFranco, Kenneth N. Muse
Abstract: An effective anti-nematode methodology entails contacting nematodes with a biologically effective amount of at least one compound according to formula I: where Q, Q?, R1, R2, and n are defined herein, or with a stereoisomer, solvate, or pharmaceutically acceptable salt of such compound.
Type:
Application
Filed:
October 15, 2010
Publication date:
February 3, 2011
Inventors:
David J. MANGELSDORF, Richard J. AUCHUS, Daniel L. MOTOLA, Carolyn L. CUMMINS, Kamalesh K. SHARMA
Abstract: The invention provides compositions comprising formula 1 steroids, e.g., 16?-bromo-3?-hydroxy-5?-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16?-bromo-3?-hydroxy-5?-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to make and use these immunomodulatory compositions and formulations.
Abstract: The invention relates to methods of promoting wound healing and reducing scar formation by administration of corticosteroids, and pharmaceutical compositions comprising corticosteroids.
Abstract: The present invention relates to a method for detecting an optimal time for embryo implantation in mammals, particularly humans. In particular, the invention relates to a method for determining the optimal time for implantation of an embryo in a mammalian endometrium comprising detecting the levels of an endocannabinoid in the early, mid and late stage of the menstrual cycle in a subject.
Abstract: Novel pharmaceutical compositions contain micronized progesterone and at least one oleic safflower oil referred to as safflower oil type II, and medicines comprising said compositions are useful in treating progesterone insufficiency in women.
Type:
Application
Filed:
June 28, 2010
Publication date:
December 30, 2010
Applicant:
EFFIK
Inventors:
Jennifer Gicquel, Didier Terracol, Roland Samoyeau
Abstract: The present invention relates to the use of a compound of formula (I), or a pharmaceutically acceptable salt, crystal form, complex, hydrate, or hydrolysable ester thereof, in the preparation of a medicament for treating a patient suffering from leukaemia, cancer or other proliferative disorder. A further embodiment relates to the use a compound of formula (I) in an assay for detecting the phosphorylation state of cellular substrates. The present invention also relates to novel compounds of formula (I), and the chemical synthesis thereof.
Type:
Grant
Filed:
May 23, 2001
Date of Patent:
December 28, 2010
Assignees:
Univerzita Palackeho v Olomouci, Univerzita Karlova V Praze
Abstract: The invention concerns a concentrated hormone pharmaceutical composition having from about 0.6 to about 80% of at least one hormone; from about 20 to about 90.4% of at least one solvent, and optionally a pharmaceutically acceptable carrier. The concentrated hormone pharmaceutical composition according to this invention provides a concentrated pharmaceutical composition that is easy to use and saves time and money to the pharmacies dealing with BHRT pharmaceutical products.
Abstract: A hormone delivery system and method are provided for administering bio identical human hormones using a combination of modalities for the treatment of human physiological conditions.
Abstract: The use of at least one aromatase inhibitor in the production of a medicament for improving the implantation and pregnancy rates for a female undergoing assisted reproduction treatment, which comprises one or more daily doses of an aromatase inhibitor (AI) for administration during assisted reproduction cycles or ovarian stimulation cycles, wherein the doses of AI are selected from amounts effective to reduce serum estradiol levels. Also disclosed are related pharmaceutical preparations and packages.
Type:
Grant
Filed:
April 17, 2002
Date of Patent:
December 7, 2010
Assignee:
Ares Trading S.A.
Inventors:
Robert F. Casper, Mohamed F. M. Mitwally
Abstract: 6-Methyloxaalkyl exemestane compounds and related compositions, as can be used, chemotherapeutically, to inhibit growth and proliferation of cancer cells.
Abstract: The 17?-cyano-19-androst-4-ene derivatives of the present invention possess gestagenic activity.
Type:
Application
Filed:
June 12, 2008
Publication date:
November 18, 2010
Applicant:
BAYER SCHERING PHARMA AG
Inventors:
Joachim Kuhnke, Jan Huebner, Rolf Bohlmann, Thomas Frenzel, Ulrich Klar, Frederik Menges, Sven Ring, Steffen Borden, Hans Peter Muhn, Katja Prelle